APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy (HE) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hepatic Encephalopathy (HE) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025179 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy (HE) Therapeutics Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy (HE) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy (HE) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy (HE) Therapeutics Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy (HE) Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy (HE) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hepatic Encephalopathy (HE) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatic Encephalopathy (HE) Therapeutics include ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt and Valeant, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Hepatic Encephalopathy (HE) Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatic Encephalopathy (HE) Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatic Encephalopathy (HE) Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Hepatic Encephalopathy (HE) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatic Encephalopathy (HE) Therapeutics Segment by Company

ASKA Pharmaceutical

COSMO PHARMACEUTICALS

Mallinckrodt

Valeant

Hepatic Encephalopathy (HE) Therapeutics Segment by Type

Probiotics

Neomycin

Lactulose

Thiamine

Rifaximin

Hepatic Encephalopathy (HE) Therapeutics Segment by Application

Acute Liver Failure

Liver Cirrhosis

Hepatic Encephalopathy (HE) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy (HE) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy (HE) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy (HE) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Hepatic Encephalopathy (HE) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatic Encephalopathy (HE) Therapeutics industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatic Encephalopathy (HE) Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Probiotics Table 3. Key Players of Neomycin Table 4. Key Players of Lactulose Table 3. Key Players of Thiamine Table 4. Key Players of Rifaximin Table 5. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Acute Liver Failure Table 7. Key Players of Liver Cirrhosis Table 8. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2021-2026) Table 11. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2027-2032) Table 13. Hepatic Encephalopathy (HE) Therapeutics Industry Trends Table 14. Hepatic Encephalopathy (HE) Therapeutics Industry Drivers Table 15. Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges Table 16. Hepatic Encephalopathy (HE) Therapeutics Industry Restraints Table 17. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Company (2021-2026) Table 19. Global Hepatic Encephalopathy (HE) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Hepatic Encephalopathy (HE) Therapeutics Key Company Head Office and Area Served Table 21. Global Hepatic Encephalopathy (HE) Therapeutics Company, Product Type & Application Table 22. Global Hepatic Encephalopathy (HE) Therapeutics Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Hepatic Encephalopathy (HE) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2027-2032) Table 35. ASKA Pharmaceutical Company Information Table 36. ASKA Pharmaceutical Business Overview Table 37. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 39. ASKA Pharmaceutical Recent Development Table 40. COSMO PHARMACEUTICALS Company Information Table 41. COSMO PHARMACEUTICALS Business Overview Table 42. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 44. COSMO PHARMACEUTICALS Recent Development Table 45. Mallinckrodt Company Information Table 46. Mallinckrodt Business Overview Table 47. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 49. Mallinckrodt Recent Development Table 50. Valeant Company Information Table 51. Valeant Business Overview Table 52. Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio Table 54. Valeant Recent Development Table 55. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 56. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 57. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 58. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 59. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026) Table 61. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032) Table 62. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 63. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 64. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 65. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 66. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026) Table 68. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032) Table 69. China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 70. China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 71. China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 72. China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 73. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 74. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 75. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 76. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 77. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026) Table 79. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032) Table 80. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 81. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 82. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 83. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 84. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026) Table 86. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy (HE) Therapeutics Product Image Figure 2. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. Probiotics Image Figure 5. Neomycin Image Figure 6. Lactulose Image Figure 7. Thiamine Image Figure 8. Rifaximin Image Figure 9. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application: 2025 VS 2032 Figure 11. Acute Liver Failure Image Figure 12. Liver Cirrhosis Image Figure 13. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Hepatic Encephalopathy (HE) Therapeutics Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2021-2032) Figure 22. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 25. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032) Figure 26. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032) Figure 27. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032) Figure 28. United States Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 29. Canada Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 31. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 32. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032) Figure 33. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032) Figure 34. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032) Figure 35. Germany Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 36. France Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. Italy Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. Russia Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 41. China Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 42. China Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032) Figure 43. China Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032) Figure 44. Asia Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 45. Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032) Figure 46. Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032) Figure 47. Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032) Figure 48. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. India Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. Australia Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032) Figure 58. Brazil Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. UAE Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 65. Chile Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Probiotics
  • Neomycin
  • Lactulose
  • Thiamine
  • Rifaximin
Applications
  • Acute Liver Failure
  • Liver Cirrhosis
Companies covered
  • ASKA Pharmaceutical
  • COSMO PHARMACEUTICALS
  • Mallinckrodt
  • Valeant

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Probiotics
  5. 1.2.3 Neomycin
  6. 1.2.4 Lactulose
  7. 1.2.5 Thiamine
  8. 1.2.6 Rifaximin
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Acute Liver Failure
  12. 1.3.3 Liver Cirrhosis
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Hepatic Encephalopathy (HE) Therapeutics Growth Trends by Region
  15. 1.5.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2021-2026)
  17. 1.5.3 Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Hepatic Encephalopathy (HE) Therapeutics Market Dynamics
  1. 2.1 Hepatic Encephalopathy (HE) Therapeutics Industry Trends
  2. 2.2 Hepatic Encephalopathy (HE) Therapeutics Industry Drivers
  3. 2.3 Hepatic Encephalopathy (HE) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy (HE) Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Hepatic Encephalopathy (HE) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Hepatic Encephalopathy (HE) Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Hepatic Encephalopathy (HE) Therapeutics Company, Product Type & Application
  5. 3.5 Global Hepatic Encephalopathy (HE) Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Hepatic Encephalopathy (HE) Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Hepatic Encephalopathy (HE) Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Hepatic Encephalopathy (HE) Therapeutics Tier 1, Tier 2, and Tier 3
4 Hepatic Encephalopathy (HE) Therapeutics Market by Type
  1. 4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Type (2021-2032)
5 Hepatic Encephalopathy (HE) Therapeutics Market by Application
  1. 5.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 ASKA Pharmaceutical
  2. 6.1.1 ASKA Pharmaceutical Company Information
  3. 6.1.2 ASKA Pharmaceutical Business Overview
  4. 6.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  6. 6.1.5 ASKA Pharmaceutical Recent Developments
  7. 6.2 COSMO PHARMACEUTICALS
  8. 6.2.1 COSMO PHARMACEUTICALS Company Information
  9. 6.2.2 COSMO PHARMACEUTICALS Business Overview
  10. 6.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  12. 6.2.5 COSMO PHARMACEUTICALS Recent Developments
  13. 6.3 Mallinckrodt
  14. 6.3.1 Mallinckrodt Company Information
  15. 6.3.2 Mallinckrodt Business Overview
  16. 6.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  18. 6.3.5 Mallinckrodt Recent Developments
  19. 6.4 Valeant
  20. 6.4.1 Valeant Company Information
  21. 6.4.2 Valeant Business Overview
  22. 6.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Valeant Hepatic Encephalopathy (HE) Therapeutics Product Portfolio
  24. 6.4.5 Valeant Recent Developments
7 North America
  1. 7.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
  2. 7.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
  3. 7.2.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
  7. 7.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
  11. 7.4.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
  3. 8.2.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
  7. 8.3.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
  11. 8.4.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
  2. 9.2 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
  3. 9.2.1 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
  7. 9.3.1 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
  3. 10.2.1 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
  7. 10.3.1 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
  11. 10.4.1 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst